

Daniel Adams, MD, MBA

Dr. Adams qualified as a medical doctor from the Tufts University School of Medicine in 2009, with a dual Masters degree in Business Administration. Dr Adams has been with the Intermountain Medical Center in Murray, Utah since 2009 when he completed a Transitional Year Internship. He is currently working in research as the Department of Medicine Chairman's Scholar. Dr. Adams will return to Tufts Medical Center to complete his residency training in diagnostic radiology.

Dr. Adams's research focuses on the appropriate utilization of the CT pulmonary angiogram (CTPA) for diagnosis of acute pulmonary embolism (PE). His current project involves a retrospective analysis using an evidence-based diagnostic algorithm including a clinical decision tool and a d-dimer assay to determine if the study was utilized appropriately. His analysis will provide an estimate for the rate of over-utilization of CTPAs for diagnosis of acute PE, as well as the rate of complications associated with CTPAs, including contrast-induced nephropathy, anaphylaxis, false-positive diagnosis, and increased risk for malignancy. Dr. Adams's research will lay the foundation for a multidisciplinary quality improvement initiative at Intermountain that will aim to increase appropriate use of CTPA, decrease inappropriate use of CTPA, and decrease complications associated with inappropriate overutilization.

As a 2010 NATF Traveling Fellow, Dr. Adams will collaborate with Dr. Samuel Z. Goldhaber at Brigham and Women's Hospital in Boston, MA to further advance his project.

Charles "Kurt" Mahan, PharmD

Dr. Mahan qualified as a doctor of pharmacy from the University of New Mexico in 2004. He received specialized anticoagulation and venous thromboembolism training from Dr. Alex Spyropoulos of Lovelace Medical Center in Albuquerque, NM. Since 2005 Dr. Mahan has worked at the Lovelace Medical Center and Rehabilitation Hospital and is currently the Director of Hospital Pharmacy.

Dr. Mahan is focused on the prevention of venous thromboembolism (VTE) with an eye on the standard of care provided both within the U.S. and internationally. He is particularly interested in better defining national medical and overall costs associated with VTE, and improving methods to reduce these costs. Dr. Mahan's VTE research is aimed at reducing overall VTE and "preventable" VTE, while increasing appropriate prophylaxis rates as defined by type, dose, and duration.

As a 2010 NATF Traveling Fellow, Dr. Mahan will collaborate with Drs. Alex Spyropoulos and Alexander Graham Turpie to validate risk assessment models for both VTE and bleeding in the medical patient. The project will involve the development of a standardized tracking form to be utilized for retrospective chart review of patients identified as having VTE and major or clinically-relevant bleeding.

Indermohan Thethi, MD

Dr. Thethi qualified as a medical doctor from Kasturba Medical College in Manipal, Karnataka, India in 2002. He completed his residency in Internal Medicine at the St. Joseph Hospital, Chicago in 2008. Dr. Thethi is currently a Hospitalist in Internal Medicine at Aurora Memorial Hospital in Burlington, WI.

Dr. Thethi's research involves inflammation in end stage renal disease (ESRD) patients. He is particularly concerned with measuring the incidence of venous thromboembolism in this patient population.

As a 2010 NATF Traveling Fellow, Dr. Thethi will collaborate with Dr. Vinod Bansal of Loyola University Medical Center to address the prevalence of plasma markers for activation of coagulation in ESRD patients. Besides using conventional assay methods, biochip array technology will be utilized both to profile these patients and in the risk stratification process. Moreover, since the ongoing program registry of these patients has been established, the prevalence of VTE will be identified. Patients with high D-dimer and increased thrombin generator makers will be identified and clinical data will be compared.